Internal Medicine, Hematology & Oncology · Carmichael, CA
NPI
1912171034
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
6555 Coyle Ave
Carmichael, CA, 95608
Phone (916) 536-3540
Groups this clinician bills Medicare through
Medicare paid, 2024
$691K
40,595 services
Medicare patients, 2024
430
Average age 74
Drug cost, 2024
$2.1M
1,299 prescriptions
Company payments, 2025
$56.93
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shahzad A Siddique was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 595 times for 20 patients. In total Shahzad A Siddique billed 40,595 services in 85 codes, and Medicare paid $691K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-04-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 595 | 20 | $0.09 | $53.31 |
| 99214 Office E&M - Established | Office | 412 | 171 | $102.72 | $42K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 390 | 15 | $0.68 | $264 |
| 99213 Office E&M - Established | Office | 160 | 130 | $75.22 | $12K |
| 96375 Injection Administration | Office | 135 | 32 | $14.24 | $1,923 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 104 | 21 | $3.28 | $342 |
| 96413 Chemotherapy Administration | Office | 96 | 34 | $117.88 | $11K |
| 96365 Intravenous Infusion, Hydration | Office | 91 | 54 | $53.22 | $4,843 |
| 36591 Vascular | Office | 68 | 24 | $23.17 | $1,576 |
| 96367 Intravenous Infusion, Hydration | Office | 55 | 19 | $26.43 | $1,454 |
| 96415 Chemotherapy Administration | Office | 54 | 21 | $25.13 | $1,357 |
| 36415 Venipuncture Blood Collection | Office | 51 | 22 | $8.48 | $433 |
| 96372 Injection Administration | Office | 50 | 19 | $12.24 | $612 |
| 96417 Chemotherapy Administration | Office | 48 | 15 | $59.77 | $2,869 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 45 | 19 | $0.63 | $28.5 |
By year: 2022 $747K for 27,804 services; 2023 $577K for 32,760 services; 2024 $691K for 40,595 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 51 | 22 | $8.48 | $433 |
Medicare prescription drug claims, 2024
In 2024, the drug Shahzad A Siddique prescribed most often to Medicare patients was Anastrozole, with 164 prescriptions and refills. In total Shahzad A Siddique wrote 1,299 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 164 | 384 | 43 | $3,370 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 151 | 151 | 32 | $4,023 |
| Morphine Sulfate Er Morphine Sulfate | 64 | 64 | Under 11 | $2,929 |
| Tamoxifen Citrate Generic | 50 | 92 | Under 11 | $959 |
| Ondansetron Hcl Generic | 43 | 43 | 30 | $517 |
| Letrozole Generic | 42 | 100 | Under 11 | $936 |
| Potassium Chloride Generic | 41 | 47 | Under 11 | $273 |
| Hydroxyurea Generic | 39 | 71 | Under 11 | $588 |
| Exemestane Generic | 31 | 77 | Under 11 | $3,509 |
| Eliquis Apixaban | 30 | 30 | Under 11 | $17K |
| Prednisone Generic | 28 | 28 | Under 11 | $150 |
| Dexamethasone Generic | 26 | 34 | Under 11 | $288 |
| Xtandi Enzalutamide | 25 | 25 | Under 11 | $344K |
| Gabapentin Generic | 23 | 36 | Under 11 | $423 |
| Inlyta Axitinib | 23 | 23 | Under 11 | $337K |
Brand drugs: 210 claims; generic drugs: 1,089 claims; opioid claims: 266.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shahzad A Siddique $56.93 ($56.93 in general payments such as food, travel and fees) from 2 companies. The largest payer was Amgen Inc. with $32.72.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.